SNP-Based Genetic Markers for Cardiovascular Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for coronary heart disease (CHD) and hypertension lack effective genetic markers for early detection and prediction, leading to inadequate identification of individuals at risk, particularly those with early-onset MI and those who may not respond to statin treatments, due to limitations in existing biomarkers and risk assessment tools.
Innovation Solution
Identification of specific single nucleotide polymorphisms (SNPs) associated with CHD, MI, and hypertension, which can be used to develop diagnostic and prognostic reagents and therapeutic agents, enabling personalized treatment approaches by predicting individual responses to statins and identifying those at increased or decreased risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods and biomarkers are used for CHD and hypertension detection, then existing clinical practice is maintained, but early detection accuracy and identification of high-risk individuals are insufficient
Solution Approach 1:
The patent changes the detection parameter from traditional clinical biomarkers to genetic polymorphism markers (SNPs). By identifying specific SNP profiles associated with CHD and hypertension risk, the method achieves more accurate early detection and more reliable identification of high-risk individuals before clinical symptoms manifest.
Solution Approach 2:
The patent enables preliminary genetic testing to identify individuals at risk for CHD and hypertension before disease onset. By detecting susceptibility polymorphisms in advance, the method allows for early intervention and preventive measures, improving both detection accuracy and risk identification reliability.
2Adaptability or versatility
If traditional risk assessment tools are used, then conventional treatment approaches are applied, but personalized treatment prediction and statin response evaluation are inadequate
Solution Approach 1:
The patent applies local quality by tailoring treatment approaches based on individual genetic profiles. Specifically, it identifies patients with polymorphisms in genes such as HMGCR, PCSK9, and APOE who may have differential responses to statin therapy, enabling customized treatment strategies rather than uniform approaches.
Solution Approach 2:
The patent incorporates feedback mechanisms by using genetic test results to guide treatment decisions. The polymorphism detection provides information about predicted treatment efficacy and adverse event risk, allowing clinicians to adjust therapy based on this genetic feedback, thereby improving personalized treatment capability while preserving treatment response information.
3Reliability
If early-onset MI patients are identified using current methods, then standard protocols are followed, but specific high-risk group detection and targeted prevention are insufficient
Solution Approach 1:
The patent enables preliminary identification of early-onset MI risk through genetic polymorphism detection in individuals before clinical events occur. By detecting susceptibility markers in young adults and middle-aged individuals, the method allows for early prevention interventions to be implemented, improving both detection accuracy and timing of preventive measures.
Data Source
AI summary
The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.